Nothing Prepares You for Investing, and Running, as Experience Does
A few key lessons from running that are also applicable to investing.
Charles Rotblut
| SECTOR | INDUSTRY |
| Health Care | Health Care Equipment & Supplies |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
A few key lessons from running that are also applicable to investing.
Charles Rotblut
Success in today's dividend investing landscape requires abandoning the outdated practice of simply chasing the highest yields.
Charles Rotblut, Doug Gerlach
Jack Gilleland
Eunice Kim
Jenna Brashear
| Share Statistics | ABT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $196,748.6 | $399.1 | 99% |
|
| Shares Out (Mil) | 1,737.9 | 40.6 | 96% |
|
| Institutional Ownership | 99.4% | 83.3% | 88% |
|
| Float (Mil) | 1,720.1 | 35.1 | 94% |
|
| Beta | 0.54 | 0.85 | 31% |
|
| Avg Daily Volume (000s) | 8,493 | 348 | 95% |
|
| Price Change (52-week) |
(9.7%) | 64.5% | 42% |
|
| Growth | ABT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 5.1% | 11.8% | 37% |
|
| Net Income (5yr) | 7.7% | (5.6%) | 52% |
|
| EPS (5yr) | 8.2% | 10.6% | 44 |
|
| Dividends (5yr) | 9.4% | 0.0% | 92% |
|
| Cash Flow (5yr) | (20.9%) | (15.6%) | 31% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 23 | 27 | 27 | |
| Current EPS | $1.638 | $5.519 | $5.937 | |
| Month Ago EPS | $1.638 | $5.519 | $6.065 | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | $1.638 | $5.517 | $6.063 | |
| Year/Year Chg | 209.1% | 48.4% | 75.0% | |
| Financials | ABT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $48,229 | $127 | 97% |
|
| Net Income (TTM) (Mil) | $4,701 | ($9) | 96% |
|
| EPS (TTM) | $2.689 | ($0.300) | 76% |
|
| Operating Cash Flow (TTM) (Mil) | $8,855 | ($1) | 97% |
|
| Net Cash Flow (TTM) (Mil) | ($3,459) | $1 | 1% |
|
| Long-Term Debt (Q1) (Mil) | $29,718 | $27 | 97% |
|
| Enterprise Value (Q1) (Mil) | $227,613 | $390 | 99% |
|
| Valuation | ABT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.86 | 2.61 | 76% |
|
| P/E | 42.2 | 26.1 | 83% |
|
| Dividend Yield | 2.2% | 0.0% | 77% |
|
| PEG (5yr hist) | 5.0 | 1.5 | 88% |
|
| Ratios | ABT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 57.2% | 59.4% | 70% |
|
| Net Margin | 9.7% | (6.2%) | 61% |
|
| ROA | 4.9% | (11.0%) | 70% |
|
| ROE | 9.2% | (9.7%) | 54% |
|
| Liabilities to Assets | 52.3% | 46.5% | 45% |
|
| F-Score | 5 | 4 | 50% |
|
Abbott Laboratories did not pass any screens on 11/5/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors